The role of Anti-Müllerian hormone in women health
Abstract
Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women. The suppressive effect of AMH on follicle-stimulating hormone (FSH)-induced aromatase production likely plays a role in hyperandrogenism in polycystic ovary syndrome (PCOS) and may increase insulin resistance. Female adolescent with type 1 diabetes (T1D) have an increased likelihood of developing PCOS, but it is not known whether they also show elevated AMH levels. The elevated AMH levels observed in prepubertal girls with T1D suggest that there are more small follicles in their ovaries, probably in response to insulin treatment. Elevated levels of androgens and anti-Müllerian hormone have been previously reported in non-pregnant women with diabetes. The increased AMH concentrations can be associated with reduced systemic inflammation [lower c-reactive protein (CRP) values], irrespective of the type of diet and greater insulin sensitivity in old obese males. AMH can also serve as a valuable marker for granulosa cell tumors (folliculomas) and their recurrence. In these clinical scenarios, AMH levels can be significantly elevated and correspond with the size of the tumor.
Keywords: anti-Müllerian hormone (AMH)hypogonadismandrogens resistancepremature ovarian failureovarian reservePCOS syndromeT1DT2Ddiabetes mellitus
References
- Jarmińska-Jackowiak T, Warenik-Szymankiewicz A, Trzeciak WH. [Anti-Mullerian hormone. Structure and role in sexual differentiation]. Ginekol Pol. 1995; 66(1): 51–58.
- Skałba P, Cygal A, Dabkowska-Huć A. [The influence of anti-Mullerian hormone on folliculogenesis]. Ginekol Pol. 2008; 79(2): 137–140.
- La Marca A, Broekmans FJ, Volpe A, et al. Anti-Müllerian hormone (AMH): what do we still need to know? Hum Reprod. 2009; 24(9): 2264–2275.
- McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000; 21(2): 200–214.
- Lee JY, Jee BC, Lee JR, et al. Age-related distributions of anti-Müllerian hormone level and anti-Müllerian hormone models. Acta Obstet Gynecol Scand. 2012; 91(8): 970–975.
- Lie Fong S, Visser JA, Welt CK, et al. Serum anti-müllerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab. 2012; 97(12): 4650–4655.
- Wender-Ożegowska E, Ożegowska K. Polycystic ovary syndrome. Not only a gynecological disorder - current state of knowledge. Diseases of civilisation in medical practice. Cardiology and Diabetology. https://www.kardiologia-i-diabetologia.pl/artykul/zespol-policystycznych-jajnikow-schorzenie-nie-tylko-ginekologiczne-aktualny-stan-wiedzy (2.05.2022).
- Czech IJ, Drosdzol-Cop A. The role of anti-Müllerian hormone (AMH) in girls and adolescents. Ginekol Pol. 2021; 92(7): 525–527.
- Hagen CP, Aksglaede L, Sørensen K, et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010; 95(11): 5003–5010.
- Codner E, Iñiguez G, Hernández IM, et al. Elevated anti-Müllerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus. Clin Endocrinol (Oxf). 2011; 74(1): 73–78.
- Fleming R, Kelsey TW, Anderson RA, et al. Interpreting human follicular recruitment and antimüllerian hormone concentrations throughout life. Fertil Steril. 2012; 98(5): 1097–1102.
- Kerkhof GF, Leunissen RWJ, Willemsen RH, et al. Influence of preterm birth and small birth size on serum anti-Müllerian hormone levels in young adult women. Eur J Endocrinol. 2010; 163(6): 937–944.
- Łebkowska A, Kowalska I. Anti-Müllerian hormone and polycystic ovary syndrome. Endokrynol Pol. 2017; 68(1): 74–78.
- Krawczyńska M, Słowińska-Srzednicka J. The utilization of anti-müllerian hormone (AMH) plasma level measurements in diagnosis of endocrine diseases. Postępy Nauk Med. 2016; 12: 921–928.
- Wikarek T, Olszanecka-Glinianowicz M, Chudek J, et al. [Anti-Müllerian hormone and fertility disturbances in obese women and women with polycystic ovary syndrome]. Ginekol Pol. 2011; 82(3): 205–209.
- Li L, Chen X, Mo Y, et al. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010; 122(17–18): 519–524.
- Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010; 95(9): 4399–4405.
- Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016; 33(1): 15–28.
- Feldman RA, O'Neill K, Butts SF, et al. Antimüllerian hormone levels and cardiometabolic risk in young women with polycystic ovary syndrome. Fertil Steril. 2017; 107(1): 276–281.
- de Kat AC, Verschuren WM, Eijkemans MJC, et al. Anti-Müllerian hormone trajectories are associated with cardiovascular disease in women: results from the doetinchem cohort study. Circulation. 2017; 135(6): 556–565.
- Efthymiadou A, Bogiatzidou M, Kritikou D, et al. Anti-Müllerian hormone in girls with premature adrenarche: the impact of polycystic ovary syndrome history in their mothers. J Pediatr. 2019; 205: 190–194.
- Verdiesen RMG, Onland-Moret NC, van Gils CH, et al. Anti-Müllerian hormone levels and risk of type 2 diabetes in women. Diabetologia. 2021; 64(2): 375–384.
- Poretsky L, Clemons J, Bogovich K. Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism. 1992; 41(8): 903–910.
- Fulghesu AM, Villa P, Pavone V, et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 1997; 82(2): 644–648.
- Park HT, Cho GJ, Ahn KiH, et al. Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010; 72(1): 26–31.
- Dorman JS, Steenkiste AR, Foley TP, et al. Menopause in type 1 diabetic women: is it premature? Diabetes. 2001; 50(8): 1857–1862.
- Soto N, Iñiguez G, López P, et al. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum Reprod. 2009; 24(11): 2838–2844.
- Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295(11): 1288–1299.
- Fenske B, Kische H, Gross S, et al. Endogenous androgens and sex hormone-binding globulin in women and risk of metabolic syndrome and type 2 diabetes. J Clin Endocrinol Metab. 2015; 100(12): 4595–4603.
- Nelson SM, Stewart F, Fleming R, et al. Longitudinal assessment of antimüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril. 2010; 93(4): 1356–1358.
- La Marca A, Giulini S, Orvieto R, et al. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005; 20(6): 1569–1572.
- Villarroel C, Salinas A, López P, et al. Pregestational type 2 diabetes and gestational diabetes exhibit different sexual steroid profiles during pregnancy. Gynecol Endocrinol. 2017; 33(3): 212–217.
- Villarroel C, Salinas A, López P, et al. Anti-Müllerian hormone in type 2 and gestational diabetes during the second half of pregnancy: relationship with sexual steroid levels and metabolic parameters. Gynecol Endocrinol. 2018; 34(2): 120–124.
- Nelson SM, Davis SR, Kalantaridou S, et al. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Hum Reprod Update. 2023; 29(3): 327–346.
